Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Diabetes

US drug regulator approves ‘artificial pancreas’ pump for diabetics

The US Food and Drug Administration (FDA) has approved the first ‘artificial pancreas’ insulin pump for type 1 diabetics, which constantly monitors blood sugar to provide the correct dose.

Medtronic’s MiniMed 670G measures glucose levels every five minutes through a sensor that attaches to the skin and automatically alters the dose of insulin given through an infusion patch connected to the insulin pump, which is attached to the body with a strap. The hormone is then delivered to the patient through a catheter.

Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, says: “This first-of-its-kind technology can provide people with type 1 diabetes greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin.”

It is the first FDA-approved device that is intended to automatically monitor glucose and provide basal insulin doses for patients with type 1 diabetes over the age of 14 years.

While the device automatically adjusts insulin levels, users need to manually request insulin doses to counter the effects of eating a meal.

The FDA had considered results from a clinical trial of 123 patients with type 1 diabetes which tested the device over a three-month period, with the regulator saying it had worked with the company from the earliest stages to get the technology to patients as quickly as possible.

Although it has been shown to be safe with no severe adverse effects reported, the FDA says a post-market study will be set up to monitor how MiniMed performs in real-world settings.

Medtronic is currently evaluating the device in children aged 7–13 years. It is not recommended for patients under the age of six years or patients who require less then eight units of insulin a day.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201775

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Medtronic building

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.